Vertex Pharma (VRTX) Misses Q2 EPS by 113c; raises guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Vertex (VRTX) PT Raised to $576 at Wolfe Research
August 5, 2024 5:19 AM EDTWolfe Research analyst Andy Chen raised the price target on Vertex (NASDAQ: VRTX) to $576.00 (from $520.00) while maintaining a Outperform rating.
The analyst comments "Revenue & earnings in-line. Now what after the bull run? Little incremental news aside from two exhibits on T1D. Our... More
